期刊
JOURNAL OF NEUROIMMUNE PHARMACOLOGY
卷 16, 期 2, 页码 376-389出版社
SPRINGER
DOI: 10.1007/s11481-020-09931-w
关键词
Nanoparticles loaded T cells; Anti-CD20; Drug delivery; EAE
资金
- Regione Toscana, project INSIDE, FESR 2014-2020
A nanotechnology-based drug delivery system using myelin antigen-specific T cells loaded with nanoparticles bound to anti-CD20 antibody was developed for treating multiple sclerosis. The system effectively depleted B cells in the spleen and brain in mice, showing promise in ameliorating spinal cord inflammation and pathology in a MS animal model.
We developed a nanotechnology based-cell mediated drug delivery system by loading myelin antigen-specific T cells with nanoparticles bound to anti-CD20 monoclonal antibody. Anti-CD20 antibody is a current treatment (ocrelizumab) for multiple sclerosis (MS), a chronic, inflammatory and autoimmune disease of the central nervous system (CNS). CD20-depletion has been associated with efficacy in active relapsing and progressive MS, but may not efficiently target inflammatory cells compartmentalized in the CNS. In our work, the intravenous transfer of T cells containing nanoparticle-anti-CD20 complex in mice causes B cell depletion in the spleen and in the brain, whereas the injection of anti-CD20 alone depletes B cells only in the spleen. Testing this system in Experimental Autoimmune Encephalomyelitis (EAE), animal model of MS, we found that spinal cord B cell depletion ameliorates the disease course and pathology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据